GT Biopharma, Inc. (NASDAQ:GTBP) Sees Large Increase in Short Interest

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 19,300 shares, an increase of 14.9% from the July 31st total of 16,800 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 42,500 shares, the short-interest ratio is currently 0.5 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GT Biopharma stock. DekaBank Deutsche Girozentrale acquired a new stake in GT Biopharma, Inc. (NASDAQ:GTBP) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned approximately 77.02% of GT Biopharma at the end of the most recent quarter. 8.15% of the stock is owned by institutional investors.

GT Biopharma Stock Down 1.4 %

Shares of GT Biopharma stock traded down $0.03 during trading hours on Monday, hitting $2.15. The company’s stock had a trading volume of 5,100 shares, compared to its average volume of 530,202. The stock has a 50 day moving average of $2.56 and a 200 day moving average of $3.42. GT Biopharma has a 12 month low of $2.07 and a 12 month high of $10.66.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.